Article Dans Une Revue Applied and Environmental Microbiology Année : 2024

Reduction of product composition variability using pooled microbiome ecosystem therapy and consequence in two infectious murine models

Julie Reygner
  • Fonction : Auteur
  • PersonId : 1019741
Bastien Laperrousaz

Résumé

Growing evidence demonstrates the key role of the gut microbiota in human health and disease. The recent success of microbiotherapy products to treat recurrent Clostridioides difficile infection has shed light on its potential in conditions associated with gut dysbiosis, such as acute graft-versus-host disease, intestinal bowel diseases, neurodegenerative diseases, or even cancer. However, the difficulty in defining a “good” donor as well as the intrinsic variability of donor-derived products’ taxonomic composition limits the translatability and reproducibility of these studies. Thus, the pooling of donors’ feces has been proposed to homogenize product composition and achieve higher taxonomic richness and diversity. In this study, we compared the metagenomic profile of pooled products to corresponding single donor-derived products. We demonstrated that pooled products are more homogeneous, diverse, and enriched in beneficial bacteria known to produce anti-inflammatory short chain fatty acids compared to single donor-derived products. We then evaluated pooled products’ efficacy compared to corresponding single donor-derived products in Salmonella and C. difficile infectious mouse models. We were able to demonstrate that pooled products decreased pathogenicity by inducing a structural change in the intestinal microbiota composition. Single donor-derived product efficacy was variable, with some products failing to control disease progression. We further performed in vitro growth inhibition assays of two extremely drug-resistant bacteria, Enterococcus faecium vanA and Klebsiella pneumoniae oxa48, supporting the use of pooled microbiotherapies. Altogether, these results demonstrate that the heterogeneity of donor-derived products is corrected by pooled fecal microbiotherapies in several infectious preclinical models.

Fichier principal
Vignette du fichier
aem.00016-24.pdf (3.04 Mo) Télécharger le fichier
Origine Accord explicite pour ce dépôt
Licence

Dates et versions

hal-04872718 , version 1 (08-01-2025)

Licence

Identifiants

Citer

Julie Reygner, Johanne Delannoy, Marie-Thérèse Barba-Goudiaby, Cyrielle Gasc, Benoît Levast, et al.. Reduction of product composition variability using pooled microbiome ecosystem therapy and consequence in two infectious murine models. Applied and Environmental Microbiology, 2024, 90 (5), pp.00016-24. ⟨10.1128/aem.00016-24⟩. ⟨hal-04872718⟩
115 Consultations
112 Téléchargements

Altmetric

Partager

  • More